Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Spotlight: Distalmotion Wants To Bring Cost-Effective, Focused Alternative To Robotic Surgery Market

Executive Summary

Switzerland-based Distalmotion hopes to make its Dexter robotic surgery the standard of care in procedures that entail precise dissection and suturing and market itself as a more cost-effective alternative to Intuitive Surgical’s da Vinci system.

You may also be interested in...



Market Brief: Global Market For Endoscopic Surgeries Will Reach $17.7Bn In 2023

The global market for endoscopic and pelvic surgery procedures is expected to reach $17.7bn in 2023, a CAGR of 6.4%, driven by patients' demand for less invasive surgeries and physicians' preference for minimally invasive surgeries versus open surgeries. By 2023, the number of general and pelvic endoscopic procedures performed globally will reach about 29.7 million, representing a CAGR of 3.6%.

SAGES 2019: Spotlighting Competitive Robotic Systems And Procedures

Surgical robotics giant Intuitive Surgical will soon face competition from Medtronic and Verb Surgical. With the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting on the way in Baltimore, MD this week, Wells Fargo analyst Larry Biegelsen offers an outlook on competitive robotic systems and the rising popularity by surgeons to use robotics systems in hernia, bariatric, cholecystectomy and colorectal procedures.

What’s Under The Iceberg: GE Healthcare’s Deep Dive Look At Future Of Gene Therapy

Cell and gene therapy represent a transformative advance in drug delivery and outcomes, with implications equally as important to human progress as the digital revolution that began three decades ago.In Vivo speaks with a key player in this evolving field, GE Healthcare’s strategy manager for cell and gene therapy and board member of the Alliance for Regenerative Medicine, Phil Vanek, PhD.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel